Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Improving COVID-19 critical care mortality over time in England: A national cohort study, March to June 2020

View ORCID ProfileJohn M. Dennis, View ORCID ProfileAndrew P. McGovern, Sebastian J. Vollmer, View ORCID ProfileBilal A. Mateen
doi: https://doi.org/10.1101/2020.07.30.20165134
John M. Dennis
1University of Exeter Medical School. Address: Institute of Biomedical & Clinical Science, RILD Building, Royal Devon & Exeter Hospital, Barrack Road, Exeter EX2 5DW, UK
(PhD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for John M. Dennis
Andrew P. McGovern
1University of Exeter Medical School. Address: Institute of Biomedical & Clinical Science, RILD Building, Royal Devon & Exeter Hospital, Barrack Road, Exeter EX2 5DW, UK
(MD Res)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andrew P. McGovern
Sebastian J. Vollmer
2The Alan Turing Institute. Address: British Library, 96 Euston Road, London, NW1 2DB, UK
3University of Warwick, Department of Statistics. Address: Department of Statistics, University of Warwick, Coventry, CV4 7AL, UK
(PhD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bilal A. Mateen
2The Alan Turing Institute. Address: British Library, 96 Euston Road, London, NW1 2DB, UK
4Kings College Hospital NHS Foundation Trust. Address: Hambleden Wing, Kings College Hospital, Denmark Hill, London, SE5 9RS, UK
5University of Warwick Medical School, Social Science and Systems in Health Unit. Address: Medical School Building, University of Warwick, Coventry, CV4 7AL, UK
(MBBS)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bilal A. Mateen
  • For correspondence: b.mateen@warwick.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Objectives To determine the trend in mortality risk over time in people with severe COVID-19 requiring critical care (high intensive unit [HDU] or intensive care unit [ICU]) management.

Methods We accessed national English data on all adult COVID-19 specific critical care admissions from the COVID-19 Hospitalisation in England Surveillance System (CHESS), up to the 29th June 2020 (n=14,958). The study period was 1st March until 30th May, meaning every patient had 30 days of potential follow-up available. The primary outcome was in-hospital 30-day all-cause mortality. Hazard ratios for mortality were estimated for those admitted each week using a Cox proportional hazards models, adjusting for age (non-linear restricted cubic spline), sex, ethnicity, comorbidities, and geographical region.

Results 30-day mortality peaked for people admitted to critical care in early April (peak 29.1% for HDU, 41.5% for ICU). There was subsequently a sustained decrease in mortality risk until the end of the study period. As a linear trend from the first week of April, adjusted mortality risk decreased by 11.2% (adjusted HR 0.89 [95% CI 0.87 - 0.91]) per week in HDU, and 9.0% (adjusted HR 0.91 [95% CI 0.88 - 0.94]) in ICU.

Conclusions There has been a substantial mortality improvement in people admitted to critical care with COVID-19 in England, with markedly lower mortality in people admitted in mid-April and May compared to earlier in the pandemic. This trend remains after adjustment for patient demographics and comorbidities suggesting this improvement is not due to changing patient characteristics. Possible causes include the introduction of effective treatments as part of clinical trials and a falling critical care burden.

Competing Interest Statement

SJV declares funding from IQVIA. APM declares previous research funding from Eli Lilly and Company, Pfizer, and AstraZeneca. All other authors declare no competing interests.

Clinical Trial

na

Funding Statement

There was no direct funding for this study. JMD is supported by an Independent Fellowship funded by Research Englands Expanding Excellence in England (E3) fund. SJV, and BAM are supported by The Alan Turing Institute (EPSRC grant EP/N510129/). SJV is supported by the University of Warwick IAA funding.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was reviewed and approved by the Warwick BSREC (BSREC 119/19-20-V1.1) and sponsorship is being provided by University of Warwick (SOC.28/19-20).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Updated COI, and guarantor statements, as well as affiliations.

Data Availability

Data cannot be shared publicly as it was collected by Public Health England (PHE) as part of their statutory responsibilities, which allows them to process patient confidential data without explicit patient consent. Data utilised in this study were made available through an agreement between the University of Warwick and PHE. Individual requests for access to CHESS data are considered directly by PHE (contact via covid19surv{at}phe.gov.uk)

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted August 03, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Improving COVID-19 critical care mortality over time in England: A national cohort study, March to June 2020
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Improving COVID-19 critical care mortality over time in England: A national cohort study, March to June 2020
John M. Dennis, Andrew P. McGovern, Sebastian J. Vollmer, Bilal A. Mateen
medRxiv 2020.07.30.20165134; doi: https://doi.org/10.1101/2020.07.30.20165134
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Improving COVID-19 critical care mortality over time in England: A national cohort study, March to June 2020
John M. Dennis, Andrew P. McGovern, Sebastian J. Vollmer, Bilal A. Mateen
medRxiv 2020.07.30.20165134; doi: https://doi.org/10.1101/2020.07.30.20165134

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Systems and Quality Improvement
Subject Areas
All Articles
  • Addiction Medicine (270)
  • Allergy and Immunology (552)
  • Anesthesia (135)
  • Cardiovascular Medicine (1760)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (312)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (659)
  • Epidemiology (10799)
  • Forensic Medicine (8)
  • Gastroenterology (592)
  • Genetic and Genomic Medicine (2950)
  • Geriatric Medicine (287)
  • Health Economics (534)
  • Health Informatics (1928)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (292)
  • HIV/AIDS (630)
  • Infectious Diseases (except HIV/AIDS) (12518)
  • Intensive Care and Critical Care Medicine (692)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (324)
  • Neurology (2799)
  • Nursing (151)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1467)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (866)
  • Pharmacology and Therapeutics (366)
  • Primary Care Research (337)
  • Psychiatry and Clinical Psychology (2640)
  • Public and Global Health (5370)
  • Radiology and Imaging (1013)
  • Rehabilitation Medicine and Physical Therapy (596)
  • Respiratory Medicine (726)
  • Rheumatology (330)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (150)
  • Urology (125)